Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision-Reference-Cited by-同舟云学术

Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision

Published:2024-01-11 Issue:2 Volume:29 Page:105-135
ISSN:1323-7799
Container-title:Respirology
language:en
Short-container-title:Respirology

Author:

Mackintosh John A.¹²^ORCID,Keir Gregory³^ORCID,Troy Lauren K.⁴⁵,Holland Anne E.²⁶⁷^ORCID,Grainge Christopher⁸^ORCID,Chambers Daniel C.¹²^ORCID,Sandford Debra²⁹¹⁰,Jo Helen E.⁴⁵,Glaspole Ian²¹¹^ORCID,Wilsher Margaret¹²^ORCID,Goh Nicole S. L.¹³¹⁴¹⁵^ORCID,Reynolds Paul N.²⁹¹⁰^ORCID,Chapman Sally¹⁶,Mutsaers Steven E.¹⁷,de Boer Sally¹²,Webster Susanne⁴,Moodley Yuben²¹⁶¹⁷^ORCID,Corte Tamera J.²⁴⁵^ORCID

Affiliation:

1. Department of Respiratory Medicine The Prince Charles Hospital Brisbane Queensland Australia

2. Centre of Research Excellence in Pulmonary Fibrosis Camperdown New South Wales Australia

3. Department of Respiratory Medicine Princess Alexandra Hospital Brisbane Queensland Australia

4. Department of Respiratory and Sleep Medicine Royal Prince Alfred Hospital Camperdown New South Wales Australia

5. University of Sydney Sydney New South Wales Australia

6. Department of Physiotherapy The Alfred Hospital Melbourne Victoria Australia

7. Department of Respiratory Research@Alfred Central Clinical School, Monash University Melbourne Victoria Australia

8. Department of Respiratory Medicine John Hunter Hospital Newcastle New South Wales Australia

9. Department of Thoracic Medicine Central Adelaide Local Health Network Adelaide South Australia Australia

10. University of Adelaide Adelaide South Australia Australia

11. Department of Respiratory Medicine The Alfred Hospital Melbourne Victoria Australia

12. Department of Respiratory Medicine Te Toka Tumai Auckland Auckland New Zealand

13. Department of Respiratory Medicine Austin Hospital Melbourne Victoria Australia

14. Institute for Breathing and Sleep Melbourne Victoria Australia

15. University of Melbourne Melbourne Victoria Australia

16. Institute for Respiratory Health, University of Western Australia Nedlands Western Australia Australia

17. Department of Respiratory Medicine Fiona Stanley Hospital Murdoch Western Australia Australia

Abstract

AbstractIdiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti‐fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non‐IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non‐pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi‐faceted approach to the management of IPF and progressive pulmonary fibrosis.

Funder

National Health and Medical Research Council

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/resp.14656

Reference291 articles.

1. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia

2. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

3. Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in Australia

4. Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis

5. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases